Shattuck Labs (STTK) Return on Capital Employed (2020 - 2026)
Shattuck Labs (STTK) posted quarterly Return on Capital Employed of 57.04% for Q1 2026, up 4051.0% year-over-year from 1.37% in Q1 2025, and up 1.85% quarter-over-quarter from 58.12% in Q4 2025.
Shattuck Labs (STTK) Return on Capital Employed (2020 - 2026) Analysis & Trends
Shattuck Labs (STTK) has reported Return on Capital Employed for 7 consecutive years, with 57.04% the latest figure, recorded in Q1 2026.
- In Q1 2026, Return on Capital Employed rose 4051.0% year-over-year to 57.04%; the TTM figure through Mar 2026 stood at 57.04% (up 4051.0% YoY), while the FY2025 annual figure was 61.33%, up 789.0% from the prior year.
- Return on Capital Employed improved to 57.04% in Q1 2026 per STTK's latest filing, from 58.12% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 21.3% in Q1 2022 and bottomed at 99.31% in Q2 2025.
- Historically, Return on Capital Employed has averaged 63.87% across 5 years, with a median of 65.17% in 2024.
- Annual changes were most pronounced in 2023 — Return on Capital Employed slumped 4598 bps — and 2026, when it jumped 4051 bps.
- Shattuck Labs' Return on Capital Employed stood at 54.62% in 2022, then retreated by 26 bps to 68.85% in 2023, then retreated by 27 bps to 87.13% in 2024, then soared by 33 bps to 58.12% in 2025, then gained by 2 bps to 57.04% in 2026.
- Business Quant data shows STTK's Return on Capital Employed at 57.04% in Q1 2026, 58.12% in Q4 2025, and 75.02% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | Shattuck Labs | 962.96 Mn | 962.96 Mn | - | -36.30% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -36.30% |
| Mar 31, 2026 | -57.04% |
| Dec 31, 2025 | -58.12% |
| Sep 30, 2025 | -75.02% |
| Jun 30, 2025 | -99.31% |
| Mar 31, 2025 | -97.55% |
| Dec 31, 2024 | -87.13% |
| Sep 30, 2024 | -74.12% |
| Jun 30, 2024 | -73.95% |
| Mar 31, 2024 | -65.17% |
| Dec 31, 2023 | -68.85% |
| Sep 30, 2023 | -77.08% |
| Jun 30, 2023 | -62.49% |
| Mar 31, 2023 | -57.45% |
| Dec 31, 2022 | -54.62% |
| Sep 30, 2022 | -31.10% |
| Jun 30, 2022 | -25.42% |
| Mar 31, 2022 | -21.30% |
| Dec 31, 2021 | -16.17% |
| Sep 30, 2021 | -22.37% |